Tag: Octagam
-
How Lisraya Targets Dermatomyositis Through TYK2/JAK1 Inhibition
Lisraya (brepocitinib) inhibits TYK2 and JAK1, reducing STAT-dependent inflammatory signaling involved in skin and muscle inflammation in dermatomyositis.
Lisraya (brepocitinib) inhibits TYK2 and JAK1, reducing STAT-dependent inflammatory signaling involved in skin and muscle inflammation in dermatomyositis.